Gilead Collaborates With Insitro To Develop NASH Therapies
Zacks Investment Research | Apr 16, 2019 11:03PM ET
Gilead Sciences Inc. (NASDAQ:GILD) announced a strategic collaboration with a privately-held, data-driven drug discovery and development company, Insitro, for discovering and developing therapies targeting nonalcoholic steatohepatitis (“NASH”).
Despite the failure of its late-stage NASH candidate earlier this year, Gilead remains committed to developing treatment for the indication.
Insitro, formed last year, focuses on using machine learning, an advanced form computer technology, to help pharma companies discover and develop drugs.
Per the terms of the collaboration deal, Gilead will use Insitro’s proprietary platform over the next three years to develop five potential therapies for NASH. In return, Gilead will pay Insitro an upfront payment of $15 million and $35 million in near-term operational milestone payments. Insitro will also be eligible to receive $200 million for each of the five therapies in pre-clinical, clinical, regulatory and commercial milestones from Gilead. Insitro will also receive tiered royalties on net sales upon potential commercialization of the therapies. The deal also includes profit sharing in China and milestone payments and royalties on other ex-U.S. sales.
Gilead’s stock has gained 3.2% in the year so far compared with the announced its intention to collaborate with Novo Nordisk (NYSE:NVO) for developing treatments for NASH. Gilead also announced a grant program for supporting investigator-sponsored clinical studies for evaluating NASH therapies this month.
A chronic liver disease, NASH is caused by excessive fat accumulation in the liver or steatosis. Per records, it has affected up to 15 million people in the United States and could cause inflammation, hepatocellular injury, progressive fibrosis and cirrhosis. The ailment is anticipated to be the leading reason behind liver transplants by 2020. Currently, NASH is the primary reason for liver transplants in people under 50 in the United States. Such patients also suffer from obesity and type II diabetes. With no treatments currently approved to address this disease, the market opportunity is huge and many companies are investing the major chunk of their R&D budget on the same.
A huge unmet need for NASH therapies has led several pharma giants including Allergan (NYSE:AGN) and Merck (NYSE:MRK) among others to develop their candidates targeting the disease.
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.